课题基金 / 基金详情

Innate Immune Mechanisms Contributing to Cancer Growth in Obesity

Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
肥胖导致癌症生长的先天免疫机制
批准号:
10706825
负责人:
EDGAR G. ENGLEMAN
金额:
$23.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30

项目摘要

项目成果

EDGAR G. ENGLEMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Supplement Project Summary Obesity (body mass index ≥30 kg/m2), which affects at least one-third of the U.S. population, is more prevalent among African American and Hispanic populations and increases the risks of both developing and dying from certain cancers. However, the cellular and molecular mechanisms underlying these risks are unknown. Our studies demonstrate that colorectal cancer (CRC) and other tumors grow considerably faster in diet-induced obese mice due to the immunosuppressive actions of the acid-sensing receptor, G-protein coupled 65 (GPR65), on tumor-associated macrophages (TAMs). In the parent project, we are analyzing the intracellular signals from GPR65 that alter TAM function and tumor growth in obese mice, identifying the mechanism by which a high-fat diet (HFD) promotes GPR65 signaling in TAMs, and assessing the effects of targeting GPR65 for tumor immunotherapy in obese and non-obese mice. Data from the parent project indicate that altered lipid metabolism is responsible for upregulating GPR65 expression on TAMs in the tumors of obese mice. Since the lipid profile in tumors of obese humans is nearly identical to that of tumors from obese mice, we believe there is a high likelihood that tumors from obese humans will display a similar immune profile. In the proposed supplement project, we will extend our studies to human cancers including CRC, hepatocellular carcinoma (HCC), pancreatic adenocarcinoma (PDAC) and breast carcinomas in order to test the hypothesis that GPR65 expression on TAMs is associated with obesity, altered TAM function and alterations of other immune cells in the tumor microenvironment. We further hypothesize that these effects of obesity on immune cells in cancer are equivalent in African American, Hispanic, Asian and non-Hispanic White populations and not determined on the basis of race or ethnicity. To analyze the tumors, we will use mass cytometry (CyTOF) to examine the frequencies, surface, and cytokine profiles of immune cells in the tumor, use single cell RNA sequencing (scRNA seq) to analyze the functional profiles of these cells and use CODEX to analyze the spatial relationships between TAMs and other immune cells. We will then compare the results between tumors from patients of different racial and ethnic backgrounds. The results of these experiments are expected to confirm both of our hypotheses and provide a strong rationale for future studies in which these hypotheses are tested in larger populations, and novel therapies targeting GPR65 are developed and evaluated in clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1 Mouse Models Analysis
  • 批准号:
    10729466
  • 项目类别:
  • 资助金额:
    $56.36万
  • 财政年份:
    2023
  • 负责人:
    EDGAR G. ENGLEMAN
  • 依托单位:
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic Progression
  • 批准号:
    10729464
  • 项目类别:
  • 资助金额:
    $191.91万
  • 财政年份:
    2023
  • 负责人:
    EDGAR G. ENGLEMAN
  • 依托单位:
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
  • 批准号:
    10704089
  • 项目类别:
  • 资助金额:
    $42.16万
  • 财政年份:
    2021
  • 负责人:
    EDGAR G. ENGLEMAN
  • 依托单位:
Targeting Lymph Node Dependent Immune Tolerance in Cancer
  • 批准号:
    10210557
  • 项目类别:
  • 资助金额:
    $53.17万
  • 财政年份:
    2021
  • 负责人:
    EDGAR G. ENGLEMAN
  • 依托单位:
国内基金
海外基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
  • 批准号:
    22007039
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    王黎明
  • 依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
  • 批准号:
    21172061
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2011
  • 负责人:
    许新华
  • 依托单位: